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Abstract
Background: Endometriosis is associated with the growth of endometrium in ectopic sites mainly within the pelvis.
This results in inflammation and scarring, causing pain and impaired quality of life. Endometriotic lesions can be
excised or ablated surgically, but the risk of recurrence is high. A Heath Technology Assessment commissioning call
in 2011 sought applications for trials aimed at evaluating long-term effectiveness of postoperative, long-acting,
reversible contraceptives (LARCs) in preventing recurrence of endometriosis. A survey of gynaecologists indicated
that there was no consensus about which LARC (Levonorgestrel Intrauterine System (LNG-IUS) or depot
medroxyprogesterone acetate injection (DMPA)) or comparator (combined oral contraceptive pill (COCP) or no
treatment) should be evaluated. Hence, we designed a ‘flexible-entry’ internal pilot to assess whether a four-arm
trial was feasible including a possible design adaption based on pilot findings.
Methods: In this pilot, women could be randomised to two, three or four treatment options provided that one
was a LARC and one was a non-LARC. An assessment of feasibility based on recruitment to these options and a
revised substantive trial design was considered by an independent oversight committee.
Results: The study ran for 1 year from April 2014 and 77 women were randomised. Only 5 (6%) women accepted
randomisation to all groups, with 63 (82%) having a LARC preference and 55 (71%) a non-LARC preference. Four-way
and three-way designs were ruled out with a two-way LARC versus COCP design, stratified by prerandomisation choice
of LARC and optional subrandomisation to LNG-IUS versus DMPA considered a feasible substantive study.
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Conclusions: Multi-arm studies are potentially efficient as they can answer multiple questions simultaneously but are
difficult to recruit to if there are strong patient or clinician preferences. A flexible approach to randomisation in a pilot
phase can be used to assess feasibility of such studies and modify a trial design based on chosen recruitment options,
but trialists should consider carefully any practical arrangements should groups need to be dropped during a study.
Trial registration: International Standard Randomised Controlled Trial Number, ISRCTN97865475. Registered on 20
March 2014.
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Background
Endometriosis affects up to one in ten women, poses a
considerable socioeconomic burden and has serious
impact on quality of life. It is associated with growth of
endometrium in abnormal locations such as the pelvic
peritoneum, ovaries, fallopian tubes, bladder and bowel.
These deposits undergo cyclical proliferation in response
to ovarian hormones (mainly oestrogen) resulting in
internal bleeding and inflammation, followed by scarring
and adhesion formation. This results in pain, and has a
profound negative impact on quality of life [1]. The ‘gold
standard’ for the diagnosis of endometriosis is laparos-
copy, a key-hole surgical procedure that allows direct
visualisation and biopsy of endometriotic tissue. Surgical
removal or destruction of endometriotic tissue is
currently the preferred treatment for pain and other
symptoms but relapse of symptoms occurs in 40–45% of
women and 27% of women are readmitted for surgery
within 5 years [2]. Half of all women diagnosed with
endometriosis require a second operation and just over
a quarter will undergo three or more procedures. Given
the substantial cost, morbidity and prolonged recovery
period associated with repeat surgery, there is an urgent
need to identify an effective means of reducing the risk
of symptom recurrence.
A 2004 Cochrane review [3] could not find sufficient
evidence in favour of any medical treatment after con-
servative surgery. There were no long-term studies, with
only some small trials considered to be lacking in quality
or size to guide practice. In November 2011 the National
Institute for Health Research Health Technology Assess-
ment Programme (NIHR HTA) in the UK issued a
commissioned call for trials evaluating ‘the clinical and
cost-effectiveness of long-acting reversible contracep-
tives (LARCs) in preventing recurrence of endometri-
osis?’ LARCs are a group of hormonal treatments of
particular interest as they are relatively cheap and have a
prolonged duration of action, eliminating the need for
daily administration, potentially improving patient com-
pliance [4]. The patient group were to be women with
endometriosis who had just been treated by surgical
treatment with the main outcome of interest being the
recurrence of symptoms in the long term (minimum
duration of follow-up at least 3 years). The applicants
were asked to justify the type of LARC that they thought
most appropriate; the example options indicated
included levonorgestrel intrauterine systems (LNG-IUS),
a uterine insert than can last for up to 5 years, and depot
medroxyprogesterone acetate injection (DMPA), an
injection that needs to be administered every 3 months.
Similarly, the applicants were asked to justify which
‘usual treatment’ should be used as the control compara-
tor; e.g. the combined oral contraceptive pill (COCP).
Gonadotropin-releasing hormone agonists (GNRHs)
were not considered suitable for inclusion as they are
not recommended for prolonged use due to risk of
osteoporosis [5].
With the evidence base unable to guide the specifics
of study design for a trial we turned to a survey of na-
tional practice in December 2011. Members of the Brit-
ish Society for Gynaecological Endoscopy were sent an
online questionnaire asking (1) whether they prescribed
postoperative hormonal treatments, (2) their most com-
monly used hormonal treatment and (3) the most rele-
vant comparison for any future trial. Sixty-two members
responded, with 56 of these having experience of treat-
ing endometriosis. Of these, 45 (80%) indicated that they
prescribed hormonal treatments and 11 (20%) did not.
GNRH, LNG-IUS, COCP, and DMPA were the most
commonly used treatments but with none obviously
preferred over the others (39, 38, 37 and 25 responses,
respectively). Three comparisons of interest ranked
higher than the others (40 responses): LNG-IUS versus
no treatment (18, 45%); LNG-IUS versus COCP (17,
43%); and LNG-IUS versus DMPA (12, 30%), but again
without any one particular favourite [6].
With no clear LARC or comparator favoured we
needed to consider how two viable LARCs: LNG-IUS
and DMPA, and two viable non-LARCs: COCP and no
treatment could be accommodated into a substantive
trial. A four-arm trial was the obvious choice but con-
cerns were raised about whether patient views would
prohibit recruitment to a design requiring consent to
four different interventions – it was likely a large pro-
portion of this population would have tried one or more
of these treatments before as they are recommended by
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NICE for the initial (presurgical) management of endo-
metriosis [7]. Pragmatic designs [8] where the patient or
clinician could select their choice of LARC or non-LARC
were considered, but concerns were raised about ultim-
ately unsatisfying and underpowered comparisons. The
non-LARC group was particularly problematic being a
mixture of active (COCP) and nonactive (no treatment)
options. Given these difficult design issues, we decided to
use feasibility of recruitment to a particular randomisation
scheme in an internal pilot phase of a larger study to guide
the type of design which should be taken forward. Here,
we report the design and findings of the internal pilot and
the proposed design of the revised study.
Methods
Design
Our proposal in the pilot phase was to include a
flexible-entry design approach where participants could
be randomised to two, three or four treatments provided
that one was a LARC and the other was a non-LARC.
This meant that a patient could enter any one of nine
randomisation schemes (Fig. 1). On completion of the
pilot phase a decision about the substantive study design
based on feasibility of recruitment would be made. As
no outcome assessment was proposed, inflation of type I
error was not a concern [9]. The options for a definitive
trial included continuing with a four-way randomisation
design if acceptable to women, or alternatively to drop
one or two treatment groups if randomisation proved
difficult. The design would be fixed along with an appro-
priate sample size target to make sure that we would
have enough power to detect a minimally important
difference [10]. Data collected from participants rando-
mised in the pilot phase to designs that remain in the
main phase would be taken forward and combined with
subsequent data collected; however, all women would be
followed up to study conclusion regardless of random-
isation options selected.
To ensure that an appropriate design choice was
made, a post-pilot phase report was scheduled to be
prepared for a joint Trial Steering Committee (TSC) –
Data Monitoring Committee (DMC) meeting to review
at the end of the pilot phase. The pilot phase was
intended to last a year with a recruitment target of 100
participants. The TSC and DMC would have the final
say on any proposed changes which would also be
communicated to the funding body for approval. The
post-pilot report was to include data on which random-
isation schemes had been selected by patients and the
results of a qualitative assessment (see below for
Fig. 1 Study design incorporating flexible entry in an internal pilot phase and possible adaptation for substantive trial phase
Middleton et al. Trials  (2017) 18:121 Page 3 of 9
methods). A threshold of any one group attracting less
than 10% of the randomisations was set as providing evi-
dence that it would not be feasible to include this group
going forward. Any updated review of external evidence
published since the grant application was submitted would
also be taken into consideration. Apart from informing
the design changes, the pilot phase also aimed to fine-tune
operational procedures, assess data capture forms and
confirm initial assumptions around sample size. The
protocol is available at http://www.nets.nihr.ac.uk/project-
sOld/hta/1111401.
Population
Women aged 16–45 years with no immediate plan to
conceive and scheduled to have laparoscopic treatment
for pelvic pain associated with surgically confirmed
endometriosis (or diagnostic laparoscopy with concur-
rent surgery if endometriosis found) were eligible.
Women were not eligible if they were being treated for
infertility, had plans for further elective endometriosis
surgery, had any suspicion of malignancy or had contra-
indications to the use of hormonal treatment.
Eligibility and randomisation
All women scheduled for surgery in the six participating
centres were approached with information regarding the
trial. They were provided with a Patient Information
Sheet and given the opportunity to ask questions. Once
eligibility was confirmed and treatment options had been
discussed, the patient was asked for informed consent
prior to surgery. Randomisation was undertaken intraop-
eratively, where feasible, to enable those allocated LNG-
IUS to have it inserted at the end of the procedure under
general anaesthetic or after conservative surgery but
prior to discharge. A web-based central randomisation
system at the University of Birmingham was used. A
minimisation algorithm was used reflecting the desire to
achieve balance with respect to a number of factors in
the overall study. Stage of endometriosis (I to IV), extent
of excision of endometriosis (complete or incomplete),
age (below 35 years or 35 years and older) and recruiting
centre were chosen as factors. A separate algorithm was
used for each of the nine study entry options. Blinding
of the patients and clinicians was not attempted as it
was felt that it was not ethically justifiable due to the dif-
fering nature of the interventions.
Procedures
Administration of the allocated medical treatment
depended on local policy; ideally this was to be initiated
prior to discharge. Subsequent injections for DMPA or
prescriptions for COCP were to be delivered by the par-
ticipant’s GP. LNG-IUS could be inserted by the
woman’s GP if not fitted at the time of operation. Those
allocated no treatment were asked to use barrier contra-
ceptive methods if required. Further details are available
in the protocol.
Sample size and statistics
The primary outcome measure for the substantive trial
was proposed to be the pain domain of the Endometri-
osis Health Profile (EHP)-30 questionnaire [11] at 3
years’ follow-up. The sample size for the substantive
study conservatively assumed to be taking forward a
four-way design and was powered (80%) to detect a 10-
point difference on the EHP-30, assuming the standard
deviation (SD) to be 25 points and type I error to be p =
0.01 (chosen through Bonferroni correction – albeit
rounded to two decimal places – to allow for six poten-
tial comparisons, i.e. all groups compared against each
other). This requires 592 patients, increased to 750 to
allow for the possibility of 20% loss to follow-up. No
hypothesis testing or formal analysis was planned for the
dissemination of the internal pilot findings, with the
primary aim to assess feasibility.
Qualitative assessment
A qualitative assessment of barriers and facilitators to
the recruitment was conducted at three of the recruiting
centres. One focus group and ten individual semistruc-
tured interviews were conducted in order to elicit
women’s past experiences with the proposed treatments
and to assess whether they constituted a barrier to par-
ticipation. The focus group discussion took place in one
of the centres and included four women. Three women
were interviewed in their homes and seven were inter-
viewed over the telephone. The focus group and inter-
views were recorded and transcribed verbatim. Content
analysis [12] was employed with a qualitative lead and
two assistants independently reading the transcripts and
agreeing upon common themes. Dissident views were
also considered. Further details are described in the
protocol.
Results
Recruitment
Six centres in the UK were involved in the pilot trial
with staggered starts from April 2014 to the end of
March 2015 (recruiting on average for 10.5 months).
During this period 504 patients were assessed for eligi-
bility with 77 patients recruited. The most common
reasons for ineligibility were: plan to conceive in the
near future (42 patients, 10%); contraindications to one
or more treatments (35 patients, 8%); no endometriosis
identified at diagnostic laparoscopy (33 patients, 8%).
The main reason for not wanting to take part was
because of a preference for a particular treatment (94
patients, 22%; the most common LNG-IUS, 30 and
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DMPA, 30). Details of randomised participants are given
in Table 1. The majority (56/77, 73%) had minimal to
mild disease and complete excision (71/77, 92%) as
judged by the operating surgeon. The average participant
rated endometriosis-related pain to be 58 (SD 19) out of
100 (worst score) as measured by the EHP-30.
Randomisation options chosen
Only 5 of the 77 participants (6%) were willing to be
randomised to all four treatment options (Fig. 2). Partici-
pants willing to be randomised to both LNG-IUS and
DMPA were relatively low, with the vast majority, 82%
(63/77), expressing a preference for one or the other in
roughly even proportions (43% for LNG-IUS and 57%
for DMPA). In a similar fashion, most, 71% (55/77)
expressed a preference for their choice of comparator in
even proportions (51% for COCP and 49% for no treat-
ment). Forty-six of the participants (60%) expressed a
preference for both a LARC and their comparator and
hence opted for variations of two-way randomisations.
Qualitative assessment
All women who agreed to participate in the qualitative
element were included in the pilot trial. They repre-
sented a range of symptomatology, treatment histories
and allocated trial treatment groups. Women found flex-
ible randomisation acceptable as they had an element of
choice over which treatment groups to be randomised
to. Half of participants (n = 7) reported that without the
option to opt out of a particular treatment group (or
groups) they would have declined trial participation. No
single treatment group was found more or less accept-
able to women. Women made decisions regarding which
treatment arms were acceptable based on their past
negative or positive treatment experiences and the treat-
ment experiences of significant others (female friends
and family). Women chose to participate in the trial for
reasons of altruism and self-interest and found the 3-
year length of their participation acceptable [13].
New external evidence
Since the initial study proposal, two systematic reviews
of variable quality have examined the use of COCP in
this population. The first [14] identified 15 randomised
trials including 850 patients. The combined odds of re-
currence was noted to be lower in the COCP group
compared with surgery alone (odds ratio (OR) 0.31, 95%
CI 0.22, 0.45; p < 0.001) The second [15] evaluated the
use of prolonged (at least 2 years) postoperative COCP
use on endometrioma recurrence in a total of 965
women (726 in cohort studies and 239 in one rando-
mised controlled trial). Recurrence was lower with
COCP compared with no treatment (OR 0.12; 95% CI
0.05–0.29; p < 0.001).
Proposal for adapted trial design
Four-way and three-way randomisation designs were
ruled out due to low numbers selecting these random-
isation options. We also ruled out a trial design involv-
ing solely the most commonly selected two-way
randomisation option (DMPA versus COCP) as this
attracted only 14 participants (18% of all participants).
Given the strong preferences noted (including in the
qualitative work) we decided to incorporate some elem-
ent of choice in the revised design (Fig. 3). The main
comparison proposed was LARC, considered as a class
of treatments, versus COCP, with LARC selected preran-
domisation by the patient if a preference was apparent
(or alternatively allocated randomly if there was no opin-
ion). The choice of LARC would need to be decided
prior to randomisation to enable unbiased stratified
(subgroup) analyses of LNG-IUS versus COCP and
DMPA versus COCP (e.g. only those selecting LNG-IUS
prerandomisation would be included in a LNG-IUS ver-
sus COCP comparison). COCP was chosen as the
Table 1 Details of participants included in the pilot phase
n = 77
Age, years Mean (SD) 31 (7.5)
Age <35 years, n (%) Yes 53 (69)
Missing 0
BMI, kg/m2 Mean (SD) 27 (5.7)
Missing 17
Ethnic group, n (%) White British 64 (86)
Black/Black British Caribbean 2 (3)
Asian/Asian British Indian 3 (4)
Asian/Asian British Pakistani 1 (1)
Mixed White/Black Caribbean 2 (3)
Mixed White/Asian 1 (1)
Other mixed background 1 (1)
Missing 3
Stage of endometriosis, n (%) I 36 (47)
II 20 (26)
III 11 (14)
IV 10 (13)
Missing 0
Ever smoked? n (%) Yes 34 (48)
Missing 6
Extent of excision as judged
by surgeon, n (%)
Complete 71 (92)
Missing 0
EHP-30 pain score Mean (SD) 58 (18.5)
Missing 2
BMI Body Mass Index, EHP Endometriosis Health Profile, SD standard deviation
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comparator over no treatment on the basis of the new
external evidence.
The sample size was revised to reflect a main two-arm
comparison and took into consideration a revised estimate
of the SD of the primary outcome (from pooled baseline
data). To detect an 8-point difference on the EHP-30 pain
domain with 90% power (p = 0.05) and assuming the SD is
22 points requires 160 participants per group, 320 in total
(to account for any loss to follow-up – estimated 20% – this
target was inflated to 400). Eight points is equivalent to
0.36 SD, which can be considered half-way between a small
(0.2 SD) to moderate (0.5 SD) effect size [16]. This size of
sample would also give us good power (80%) to detect a
10-point difference in the two stratified analyses of LNG-
IUS versus COCP and DMPA versus COCP provided the
remaining recruits into the study have a roughly even split.
Our estimates from the pilot suggest that only a minority
of patients would enter the LNG-IUS versus DMPA com-
parison but, nevertheless, some randomised data would be
better than nothing as none currently exist. This design
was ratified by the external DMC-TSC committee in April
2015 and subsequently approved by the funding body.
Fig. 2 Randomisation options chosen
Fig. 3 Revised trial design for substantive study
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Discussion
In this flexible internal pilot study of medical treatments
following surgery for endometriosis, we found that a
very low proportion of the participants were willing to
be randomised to all four treatment options on offer;
indeed most were only willing to be randomised to two
treatments that did not include both long-acting contra-
ceptives. Qualitative assessment found that women were
receptive to having some element of control over which
groups they were to be randomised to. No one particular
treatment was favoured and patient decisions were based
on previous experiences with these treatments. Mean-
while, emerging evidence suggests that COCP is more
effective for prevention of recurrence of pain following
surgery for endometriosis than no treatment in this
population. Given these findings, we revised our study
to include a main comparison of LARC versus COCP,
with LARC preselected ahead of randomisation to also
enable stratified analysis of DMPA versus COCP and
LNG-IUS versus COCP.
Where multiple treatment options are possible, a flex-
ible approach to randomisation in an internal pilot is
one that could be applicable in settings outside of gynae-
cology. Flexible trial designs have proved beneficial in
other trial situations [17, 18], allowing multiple ques-
tions to be simultaneously addressed, but often the flexi-
bility is provided to accommodate clinician preferences
or practice, rather than those of the participants. The
advantage of this approach is that it allowed the trial
team to engage with, and listen to, patients faced with
real-life decisions regarding randomisation (as opposed
to data from a survey of potential participants). An
easier choice would have been to plan a two-group trial
which could have limited the number of questions that
could be potentially answered or, alternatively, to
embark on a four-arm trial that was incapable of recruit-
ing. The assessment of the randomisation data was pre-
planned and was overseen and approved by an external,
independent committee including expert clinical and
statistical advisors. We believe our revised design to be
feasible and it enables us to include three of the four
options initially identified and at the same to incorporate
some element of patient choice which was very apparent.
We also hope that this element of patient choice will
result in faster recruitment than other design alterna-
tives but accept that this will be not be possible to prove
conclusively.
We underestimated the strength of opinion for certain
treatments and were wrong in predicting that some
would show obviously poorer recruitment than others,
allowing these to be confidently dropped and leading to
a ‘neat’ substantive trial design. Reality was more rather
more complicated and gave us results of preference that
were less straightforward. The independent TSC/DMC
was important in this respect to make sure that we
retained a study capable of changing practice rather than
one that was just ‘easy to answer’. The decision to com-
bine two different interventions (LNG-IUS and DMPA)
into one LARC drug class for the main trial was a diffi-
cult one as, although similar pharmacologically (proges-
togen), they have very different routes of administration.
However, this was considered by the committee mem-
bers to be a pragmatic response to the pilot evidence
outlined above.
We could be criticised for not setting more stringent
decision rules for all of the numerous randomisation
scenarios; this is something that should be given further
consideration in other studies wishing to adopt this
approach. Further criticism of our approach may be that
we have actually encouraged patient preference by offer-
ing it; we cannot answer whether this is indeed true
from this research. Incorporating patient preference is
controversial but some have argued that it can increase
the generalisability of study findings [19].
Whilst other trialists have reported positive experiences
with multi-arm, multi-stage trials [20] their practical chal-
lenges should not be underestimated if one or more groups
need to be stopped mid trial. We found adaptations to be
logistically difficult and took much longer than we antici-
pated; 3 months were planned for study revisions and in
reality this was closer to 9 months. The funding body con-
sidered further peer review necessary and we were also re-
quired to revise costs in line with the reduced sample size.
In addition, changes to the case report forms, protocol,
database, Research Ethics Committee (REC) approvals,
retraining for site randomisers, etc. have all taken consider-
able work. Study designs such as this or adaptive designs
[21], whilst theoretically efficient on one hand, also have the
potential for waste in this respect; processes for rapid imple-
mentation of changed designs should be considered from
the outset to mitigate against any potential delays [22].
Endometriosis is a difficult disease to study with issues
around diagnosis, reproductive intentions of the partici-
pants and suitability of outcomes [23]. There is an ur-
gent need for research into endometriosis, with serious
gaps in the current evidence base [3]. This is the only
study registered on the WHO Trial Portal (accessed on
18 May 2016) to our knowledge researching whether
LARCs are the best way to treat women following sur-
gery to prevent recurrence of symptoms. Our findings
suggest that research in this field is likely to remain chal-
lenging with some questions, such as which LARC is
more effective (LNG-IUS or DMPA), likely to prove dif-
ficult to answer due to the strength of patient opinions.
Conclusions
There is an obvious need for large publically funded tri-
als to have feasibility assessments incorporated into their
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design. If more than two interventions are on offer, trial-
ists have the dilemma of whether to embark on a multi-
arm study, which may increase the difficulty of
recruitment, or to revert to the ease of a two-group
study. In this respect, our approach to assessing where a
multi-arm study is feasible and, if not, to design a
feasible study going forward is a novel one and may
influence the design of future studies.
Trial status
PRE-EMPT is currently recruiting into the trial with the
revised study design.
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